Get it on Google Play

Par Pharmaceutical (PRX) Receives Patent Relating to Megace ES 625 mg/5 mL Oral Suspension

September 5, 2006 11:04 AM EDT Send to a Friend
Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced that a new patent has been issued by the U.S. Patent and Trademark ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login